Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease

Clinical and Experimental Medicine

Volumn 5, Issue 1, 2005, Pages 20-30

  Martinelli, N ^a   Girelli, D ^a   Olivieri, O ^a   Cavallari, U ^a   Biscuola, M ^a   Trabetti, E ^a   Friso, S ^a   Pizzolo, F ^a   Tenuti, I ^a   Bozzini, C ^a   Villa, G ^a   Ceradini, B ^a   Sandri, M ^a   Cheng, S ^b   Grow, M A ^b   Pignatti, P F ^a   Corrocher, R ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

Coronary artery disease; Metabolic syndrome; PON1 polymorphisms

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; MULTIPLE REGRESSION; OXIDATIVE STRESS; PRIORITY JOURNAL;

AGED; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 20944435867     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-005-0060-9     Document Type: Article

References (69)

1. Lusis AJ (2000) Atherosclerosis. Nature 14:233-241
2. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 14:115-126
3. Aviram M (1999) Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 9:381-386
4. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507
5. Ng CJ, Shih DM, Kama SY, Villa N, Navab M, Reddy ST (2005) The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38:153-163
6. Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135
7. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581-1590
8. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
9. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G (2004) Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 89:2957-2962
10. Getz GS, Reardon CA (2004) Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidiol 15:261-267
11. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-287
12. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484-490
13. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442
14. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149-157
15. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449
16. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76
17. Deakin SP, James RW (2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-I. Clin Sci 107:435-447
18. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman I, Sussman JL, Tawfik DS (2004) Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11:412-419
19. Mackness B, Durrington PN, Mackness MI (1999) Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 353:468-469
20. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
21. Serrato M, Marian AJ (1995) A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008
22. Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62-66
23. Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073
24. Odawara M, Tachi Y, Yamashita K (1997) Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260
25. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569
26. Sanghera DK, Aston CE, Saha N, Kamboh MI (1998) DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62:36-44
27. Pati N, Pati U (1998) Paraoxonase gene polymorphism and coronary artery disease in Indian subjects. Int J Cardiol 66:165-168
28. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU (1999) Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48:623-627
29. Aubo C, Senti M, Marrugat J, Tomas M, Vila J, Sala J, Masia R (2000) Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators. Eur Heart J 21:33-38
30. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435-442
31. Sen-Banerjee S, Siles X, Campos H (2000) Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol 20:2120-2126
32. Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 144:639-644
33. Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W (2002) Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 98:116-122
34. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI; WISE Study Group (2003) Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72:13-22
35. Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, Huang Y, Chen D, Xu X (2005) PON1 polymorphism, diabetes mellitus, obesity and risk of myocardial infarction: modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet Med 7:58-63
36. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C (1996) The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98:883-885
37. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K (1996) Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57:69-73
38. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard JM, Cambien F (1996) The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126:299-303
39. Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ (1997) The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis 8:677-682
40. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Area M (1998) The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611-1616
41. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-264
42. Cascorbi I, Laule M, Mrozikiewicz PM, Mrozikiewicz A, Andel C, Baumann G, Roots I, Stangl K (1999) Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease. Pharmacogenetics 9:755-761
43. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, Nicholls DP, Maxwell AP, Young IS (1999) Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 56:289-298
44. Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE (2000) Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149:91-97
45. Aynacioglu AS, Kepekci Y (2000) The human paraoxonase Gln-Arg192 (Q/R) polymorphism in Turkish patients with coronary artery disease. Int J Cardiol 74:33-37
46. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
47. Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM, Ballantyne CM, Marian AJ (2001) A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 154:633-640
48. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G (2002) PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 32:9-15
49. Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197-203
50. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:689-695
51. Christiansen L, Bathum L, Frederiksen H, Christensen K (2004) Paraoxonase 1 polymorphisms and survival. Eur J Hum Genet 12:843-847
52. Rea IM, McKeown PP, McMaster D, Young IS, Patterson C, Savage MJ, Belton C, Marchegiani F, Olivieri F, Bonafe M, Franceschi C (2004) Paraoxonase polymorphism PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp Gerontol 39:629-635
53. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
55. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689
56. Reaven G (2002) Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106:286-288
57. Senti M, Tomas M, Fito M, Weinbrenner T, Covas MI, Sala J, Masia R, Marrugat J (2003) Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 88:5422-5426
58. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, Friso S, Tenuti I, Cheng S, Grow MA, Pignatti PF, Corrocher R (2004) Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 34:14-20
59. Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R (2000) Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 343:774-780
60. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R (2003) Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 44:2374-2381
61. Bozzini C, Girelli D, Tinazzi E, Olivieri O, Stranieri C, Bassi A, Trabetti E, Faccini G, Pignatti PF, Corrocher R (2002) Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. Clin Chem 48:622-628
62. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
63. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, Chen JJ, Pullinger CR, Malloy MJ, Siest G, Kane JP (1999) A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 9:936-949
64. Malin R, Laine S, Rantalaiho V, Wirta O, Pasternack A, Jokela H, Alho H, Koivula T, Lehtimaki T (2001) Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers. Free Radic Res 34:477-484
65. Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD (2003) The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res 44:1919-1926
66. Tomas M, Elosua R, Senti M, Molina L, Vila J, Anglada R, Fito M, Covas MI, Marrugat J (2002) Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonasel activity. J Lipid Res 43:713-720
67. Letellier C, Durou MR, Jouanolle AM, Le Gall JY, Poirier JY, Ruelland A (2002) Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 28:297-304
68. Barbieri M, Bonafe M, Marfella R, Ragno E, Giugliano D, Franceschi C, Paolisso G (2002) LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment of IR in healthy subjects. J Clin Endocrinol Metab 87:222-225
69. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359